Quantification of urinary total luteinizing hormone immunoreactivity may improve the prediction of ovulation time.

E3G LH core fragment LH-beta Luteinizing hormone estrone-3-glucuronide ovulation predictor kit urine women

Journal

Frontiers in endocrinology
ISSN: 1664-2392
Titre abrégé: Front Endocrinol (Lausanne)
Pays: Switzerland
ID NLM: 101555782

Informations de publication

Date de publication:
2022
Historique:
received: 24 03 2022
accepted: 19 08 2022
entrez: 24 10 2022
pubmed: 25 10 2022
medline: 26 10 2022
Statut: epublish

Résumé

Most of the currently available ovulation prediction kits provide a relatively rough estimation of ovulation time with a short fertility window. This is due to their focus on the maximum probability of conception occurring one day before ovulation, with no follow-up after LH surge until ovulation nor during the subsequent days thereafter. Earlier studies have shown that urine of reproductive age women contains at least 3 different molecular forms of luteinizing hormone (LH); 1) intact LH, 2) LH beta-subunit (LHβ) and a 3) small molecular weight fragment of LHβ, LHβ core fragment (LHβcf). The proportion of these LH forms in urine varies remarkably during the menstrual cycle, particularly in relation to the mid-cycle LH surge. In this exploratory study, we studied the potential implications of determining the periovulatory course of total LH immunoreactivity in urine (U-LH-ir) and intact LH immunoreactivity in serum (S-LH-ir) in the evaluation of the fertility window from a broader aspect with emphasis on the post-surge segment. We determined total U-LH-ir in addition to intact S-LH-ir, follicle-stimulating hormone (FSH), progesterone, and estradiol in 32 consecutive samples collected daily from 10 women at reproductive age. Inference to the non-intact U-LH-ir levels was made by calculating the proportion of total U-LH-ir to intact S-LH-ir. Total U-LH-ir increased along with LH surge and remained at statistically significantly higher levels than those in serum for 5 consecutive days after the surge in S-LH-ir. S-LH-ir returned to follicular phase levels immediately on the following day after the LH surge, whereas the same took 7 days for total U-LH-ir. The current exploratory study provides preliminary evidence of the fact that U-LH-ir derived from degradation products of LH remains detectable at peak levels from the LH surge until ovulation and further during the early postovulatory period of fecundability. Thus, non-intact (or total) U-LH-ir appears to be a promising marker in the evaluation of the post-surge segment of the fertility window. Future studies are needed to unravel if this method can improve the prediction of ovulation time and higher rates of fecundability in both natural and assisted conception.

Identifiants

pubmed: 36277692
doi: 10.3389/fendo.2022.903831
pmc: PMC9581300
doi:

Substances chimiques

Progesterone 4G7DS2Q64Y
Luteinizing Hormone, beta Subunit 0
Luteinizing Hormone 9002-67-9
Follicle Stimulating Hormone 9002-68-0
Estradiol 4TI98Z838E

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

903831

Informations de copyright

Copyright © 2022 Demir, Hero, Holopainen and Juul.

Déclaration de conflit d'intérêts

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Références

BMJ Glob Health. 2019 Apr 25;4(2):e001403
pubmed: 31139458
J Clin Endocrinol Metab. 2000 Apr;85(4):1634-40
pubmed: 10770209
Anim Reprod Sci. 2011 Apr;124(3-4):229-36
pubmed: 20869180
Hum Reprod. 2018 Jun 1;33(6):1130-1140
pubmed: 29659847
Br J Obstet Gynaecol. 1984 Jul;91(7):685-9
pubmed: 6743610
Acta Endocrinol (Copenh). 1979 Feb;90(2):336-48
pubmed: 419920
J Obstet Gynecol Neonatal Nurs. 2006 May-Jun;35(3):376-84
pubmed: 16700687
Hormones (Athens). 2022 Sep;21(3):413-420
pubmed: 35614178
Eur J Obstet Gynecol Reprod Biol. 2000 Jul;91(1):59-64
pubmed: 10817880
Pediatr Res. 1994 Aug;36(2):221-6
pubmed: 7970938
Hum Reprod. 1999 Jul;14(7):1835-9
pubmed: 10402400
J Int Med Res. 2001;29 Suppl 1:3A-13A
pubmed: 11277341
Clin Biochem Rev. 2008 Aug;29 Suppl 1:S49-52
pubmed: 18852857
Biometrics. 1982 Jun;38(2):397-406
pubmed: 7115870
Fertil Steril. 1985 Sep;44(3):328-34
pubmed: 3896861
J Steroid Biochem. 1982 Dec;17(6):695-702
pubmed: 7176659
J Clin Endocrinol Metab. 1983 Oct;57(4):792-6
pubmed: 6411753
Hum Reprod. 2013 Jan;28(1):138-51
pubmed: 23081872
Fertil Steril. 2007 Sep;88(3):684-90
pubmed: 17434509
J Steroid Biochem. 1982 Feb;16(2):345-7
pubmed: 7078170
Popul Stud (Camb). 1980 Jul;34(2):397-400
pubmed: 22077133
N Engl J Med. 1995 Dec 7;333(23):1517-21
pubmed: 7477165
Fertil Steril. 1983 May;39(5):647-55
pubmed: 6840308
NPJ Digit Med. 2019 Aug 27;2:83
pubmed: 31482137
Fertil Steril. 1998 Jul;70(1):56-9
pubmed: 9660421
J Clin Endocrinol Metab. 1996 Aug;81(8):2963-7
pubmed: 8768859
J Clin Endocrinol Metab. 1995 Apr;80(4):1457-60
pubmed: 7714124
Minerva Endocrinol (Torino). 2022 Feb 15;:
pubmed: 35166468
Adv Contracept. 1997 Jun-Sep;13(2-3):83-95
pubmed: 9288325
Epidemiology. 1995 Sep;6(5):547-50
pubmed: 8562634
J Clin Endocrinol Metab. 1992 Jan;74(1):164-71
pubmed: 1727817
Am J Obstet Gynecol. 1980 Oct 15;138(4):383-90
pubmed: 6775535
Horm Res Paediatr. 2016;85(5):301-8
pubmed: 27011314
Fertil Steril. 2011 Jun;95(7):2184-9
pubmed: 20688324
Int J Fertil. 1985;30(3):18-30
pubmed: 2867054
BMJ. 2000 Nov 18;321(7271):1259-62
pubmed: 11082086
Fertil Steril. 2005 Jun;83(6):1742-4
pubmed: 15950645
Fertil Steril. 2013 Jan;99(1):279-285.e3
pubmed: 22999798
Clin Chem. 1991 Mar;37(3):333-40
pubmed: 2004439
Reproduction. 2014 Mar 02;147(4):529-35
pubmed: 24459206
J Int Med Res. 2001;29 Suppl 1:14A-20A
pubmed: 11277337

Auteurs

And Demir (A)

New Children's Hospital, Pediatric Research Center, University of Helsinki and Helsinki University Hospital, Helsinki, Finland.

Matti Hero (M)

New Children's Hospital, Pediatric Research Center, University of Helsinki and Helsinki University Hospital, Helsinki, Finland.

Elina Holopainen (E)

Department of Obstetrics and Gynecology, University of Helsinki and Helsinki University Hospital, Helsinki, Finland.

Anders Juul (A)

Department of Growth and Reproduction, Copenhagen University - Rigshospitalet, Copenhagen, Denmark.
Department of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH